NAB-14 is a powerful and selective chemical compound that acts as a non-competitive antagonist for GluN2C and GluN2D receptors. With an IC50 value of 580 nM for GluN1/GluN2D, NAB-14 demonstrates high potency. This compound exhibits a remarkable selectivity of more than 800-fold towards recombinant GluN2C and GluN2D when compared to GluN2A and GluN2B. Furthermore, NAB-14 possesses the ability to penetrate the blood-brain-barrier effectively [1].

NAB-14 (compound 14) shows inhibition with IC 50 s of 15 μM and 5.1 μM for GluN1/2AC1/2CC2 and GluN1/2AC1/2CC2 receptors, respectively [1]. NAB-14 (20 μM; 24 h) inhibits native GluN2D-containing receptors in brain slices with no effect on native GluN2A- or GluN2B-containing NMDARs in cultures cortical neurons [1]. NAB-14 (10 μM) reduces the peak amplitude of evoked EPSCs to 55 ± 3.0%, and significantly reduced the τW of EPSC deactivation [1]. NAB-14 (10 μM) decreases the peak amplitude and charge transfer of interneuron EPSCs to 59 ± 9.9% and 63 ± 9.7%, respectively. And NAB-14 decreases τW for interneuron EPSCs from 150 ± 12 ms to 101 ± 14 ms [1].

NAB-14 (20 mg/kg; p.o.) shows high systemic exposure with peak brain free of 3.2 and 3.8 nM for mouse and rat, respectively [1]. Animal Model: Mice and rats [1] Dosage: 20 mg/kg Administration: P.o. Result: Showed high systemic exposure with peak brain free of 3.2 and 3.8 nM for mouse and rat, respectively.